Relay Therapeutics, Inc. (RLAY)
NASDAQ: RLAY · Real-Time Price · USD
3.465
+0.055 (1.61%)
Mar 14, 2025, 10:55 AM EDT - Market open
Relay Therapeutics Revenue
In the year 2024, Relay Therapeutics had annual revenue of $10.01M, down -60.83%.
Revenue (ttm)
$10.01M
Revenue Growth
-60.83%
P/S Ratio
48.68
Revenue / Employee
$38,341
Employees
261
Market Cap
587.39M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 88.82B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
RLAY News
- 15 days ago - Relay Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Updates - GlobeNewsWire
- 17 days ago - Relay Therapeutics to Participate in Two Upcoming Investor Conferences - GlobeNewsWire
- 22 days ago - Relay Therapeutics to Announce Fourth Quarter and Full Year 2024 Financial Results and Corporate Highlights on February 26, 2025 - GlobeNewsWire
- 4 weeks ago - Relay Therapeutics: A Precision Oncology Play Worth The Risk - Seeking Alpha
- 2 months ago - Relay Therapeutics to Present at 43rd Annual J.P. Morgan Healthcare Conference - GlobeNewsWire
- 3 months ago - Relay Therapeutics Announces Updated Interim Data for RLY-2608 + Fulvestrant Demonstrating Continued Maturation of Clinically Meaningful Progression Free Survival - GlobeNewsWire
- 3 months ago - Relay Therapeutics to Present Updated Clinical Data on RLY-2608 in HR+/HER2- Breast Cancer at 2024 San Antonio Breast Cancer Symposium - GlobeNewsWire
- 3 months ago - Elevar Therapeutics and Relay Therapeutics Announce Exclusive Global Licensing Agreement for Lirafugratinib in FGFR2-Driven Cholangiocarcinoma and Other Solid Tumors - GlobeNewsWire